This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study
by Zacks Equity Research
The KEYLYNK-001 study evaluating Merck's Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary goal in epithelial ovarian cancer.
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to AstraZeneca and Daiichi Sankyo's Dato-DXd for previously treated advanced EGFR-mutated NSCLC.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag
by Zacks Equity Research
FDA grants priority review to AZN's sBLA seeking expanded use of Imfinzi for muscle-invasive bladder cancer.
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ
by Kinjel Shah
LLY's Zepbound shows better weight loss than NVO's Wegovy in a study. FDA updates for MRK, RHHBY, JNJ and AZN drugs grab headlines.
AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC
by Zacks Equity Research
The FDA approves AZN's Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC study data.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC
by Zacks Equity Research
This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Analyst Blog Highlights Chevron, AstraZeneca and Arista Networks
by Zacks Equity Research
Chevron, AstraZeneca and Arista Networks are included in this Analyst Blog.
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
by Zacks Equity Research
Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis are included in this Analyst Blog.
Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success
by Kinjel Shah
RHHBY is set to acquire Poseida. MRK and AZN's late-stage studies for expanded use of new drugs meet their respective goals.
Top Stock Reports for Chevron, AstraZeneca & Arista Networks
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), AstraZeneca PLC (AZN) and Arista Networks, Inc. (ANET).
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an aggressive form of prostate cancer.
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
by Kinjel Shah
EU approval for PFE's hemophilia drug Hympavzi. Novartis upgrades its mid-term sales guidance.
VKTX Stock Loses Over $1B in a Month: How to Play the Stock?
by Sundeep Ganoria
The plunge in Viking Therapeutics' share price can be attributed to the rising competition in the sector to secure a position in the booming obesity market.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
by Zacks Equity Research
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
by Zacks Equity Research
The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
by Kinjel Shah
AZN and BAYRY announce Q3 results. ABBV's studies on schizophrenia candidate, emraclidine, fail to meet goal.
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US
by Zacks Equity Research
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time this year.
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.